Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  2016-03-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1210/jc.2015-4202PMID 26982008PMCID PMC6287507
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Baseline Adiponectin Levels Do Not Influence the Response to Pioglitazone in ACT NOW

  2014cited by this paper
• Secular Changes in U.S. Prediabetes Prevalence Defined by Hemoglobin A1c and Fasting Plasma Glucose

  2013cited by this paper
• Prediction of Diabetes Based on Baseline Metabolic Characteristics in Individuals at High Risk

  2013cited by this paper
• Prevention of Diabetes With Pioglitazone in ACT NOW

  2013cited by this paper
• Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study

  2012cited by this paper
• Trends in Death Rates Among U.S. Adults With and Without Diabetes Between 1997 and 2006

  2012cited by this paper
• Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study.

  2012cited by this paper
• Association of an intensive lifestyle intervention with remission of type 2 diabetes.

  2012cited by this paper
• Pioglitazone for diabetes prevention in impaired glucose tolerance.

  2011cited by this paper
• Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes

  2011cited by this paper
• Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes

  2010cited by this paper
• 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.

  2009cited by this paper
• From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

  2009cited by this paper
• Lifetime risk and projected population prevalence of diabetes

  2008cited by this paper
• Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus

  2007cited by this paper
• (How) Can We Prevent Type 2 Diabetes?

  2007cited by this paper
• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

  2006cited by this paper
• Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes.

  2006cited by this paper
• Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

  2006cited by this paper
• Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program.

  2005cited by this paper
• Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.

  2004cited by this paper
• Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

  2002cited by this paper
• Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.

  2001cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Hepatic dysfunction associated with troglitazone.

  1998cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• The natural history of impaired glucose tolerance in the Pima Indians.

  1988cited by this paper

• Berberine Alleviates Pancreatic β-Cell Ferroptosis and Injury in db/db Mice by Regulating the AGE/RAGE Pathway: Insight from Proteomic Analysis

  2026cites this paper
• Nonlifestyle Treatment of Prediabetes.

  2025cites this paper
• Pathobiology of Prediabetes: Understanding and Interrupting Progressive Dysglycemia and Associated Complications.

  2025cites this paper
• A Review of Prediabetes: Diagnosis, Consequences and Interventions

  2025cites this paper
• Metformin plus lifestyle interventions versus lifestyle interventions alone for the delay or prevention of type 2 diabetes in individuals with prediabetes: a meta-analysis of randomized controlled trials

  2024cites this paper
• Obesity in Prediabetic Patients: Management of Metabolic Complications and Strategies for Prevention of Overt Diabetes

  2024cites this paper
• Exploring Folklore Ecuadorian Medicinal Plants and Their Bioactive Components Focusing on Antidiabetic Potential: An Overview

  2024cites this paper
• MODERN APPROACH TO THE PREVENTION OF TYPE 2 DIABETES IN THE ELDERLY

  2023cites this paper
• Should Prediabetes be Treated Pharmacologically?

  2023cites this paper
• Diagnosis and Management of Prediabetes: A Review.

  2023cites this paper
• Interventions for Reversing Prediabetes: A Systematic Review and Meta-Analysis.

  2022cites this paper
• Historical Review of the Diagnosis of Prediabetes/Intermediate Hyperglycemia: Case for the International Criteria.

  2022cites this paper
• Pioglitazone discontinuation in patients with nonalcoholic steatohepatitis is associated with disease recurrence

  2022cites this paper
• Amelioration of diabetes and its complications by Manilkara zapota (L) P. Royen fruit peel extract and its fractions in alloxan and STZ-NA induced diabetes in Wistar rats

  2022cites this paper
• Pioglitazone, Bladder Cancer and the Presumption of Innocence.

  2022cites this paper
• Effect of linagliptin on glucose metabolism and pancreatic beta cell function in patients with persistent prediabetes after metformin and lifestyle

  2021cites this paper
• The Influence of Differing Characteristics upon the Potential for a Reversal from a State of Impaired Glucose Tolerance to One of Normal Glucose Tolerance

  2021cites this paper
• New Insights to Enhance the Desired Anti-Diabetic Compounds in Medicinal and Aromatic Plants Exposed to Abiotic Stress Factors

  2021cites this paper
• Prediabetes: challenges and opportunities

  2021cites this paper
• Baseline Predictors of Glycemic Worsening in Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study

  2021cites this paper
• Influence of Cinnamon on Glycemic Control in Individuals With Prediabetes: A Randomized Controlled Trial

  2020cites this paper
• Prevention of Type 2 Diabetes

  2020cites this paper
• Regression from prediabetes to normal glucose regulation: State of the science

  2020cites this paper
• Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure

  2020cites this paper
• Functional loss of pancreatic islets in type 2 diabetes: how can we halt it?

  2020cites this paper
• SCREENING OF THE HIGH-RISK GROUP

  2020cites this paper
• Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.

  2020cites this paper
• Pre-Diabetes and What It Means: The Epidemiological Evidence.

  2020cites this paper
• Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?

  2020cites this paper
• Diabetes mellitus and nature’s pharmacy of putative antidiabetic plants

  2019cites this paper
• EFFECTIVENESS OF TREATMENT WITH PІOGLITAZONE IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND CONCOMITANT METABOLIC SYNDROME DEPENDING ON PRESENCE RS 1801282 (PRO12ALA) POLYMORPHISM IN GENE PPAR-γ

  2019cites this paper
• DIABETES LANDMARK OUTCOME TRIALS- Glycemic Control & Prevention Summary

  2019cites this paper
• Trials Mean follow-up Population Risk , hx , age Intervention A 1 C : baseline final Results Summary of RCT Outcome Evidence

  2019cites this paper
• Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes

  2019cites this paper
• Evidence for the Prevention of Type 2 Diabetes Mellitus

  2018cites this paper
• Prediabetes and Cardiovascular Disease: Pathophysiology and Interventions for Prevention and Risk Reduction.

  2018cites this paper
• Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES).

  2018cites this paper
• Relationships between blood pressure and blood glucose among offspring of parents with type 2 diabetes: Prediction of incident dysglycemia in a biracial cohort.

  2017cites this paper
• Primary Prevention of Type 2 Diabetes: An Imperative for Developing Countries

  2017cites this paper
• Roles of Perilipins in Diseases and Cancers

  2017cites this paper
• Prediabetes: A Worldwide Epidemic.

  2016cites this paper
• The current role of thiazolidinediones in diabetes management

  2016cites this paper
• Update on pre-diabetes: Focus on diagnostic criteria and cardiovascular risk

  2016cites this paper
• Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease

  2016cites this paper
• Machine learning to predict rapid progression of carotid atherosclerosis in patients with impaired glucose tolerance

  2016cites this paper